 The duration of the study was up to 65 weeks, including a Screening Period of up to 3 weeks, a double-blind DB placebo-controlled treatment period of up to 52 weeks, and a 70 day follow-up phone call for participants who prematurely discontinued or who did not enroll in the extension study NCT 00573794 M10-223. 